Vitiligo
☆ AI Dermatology — Free Service
Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
Vitiligo ing driji luwih angel diobati tinimbang wilayah liyane. Kajaba saka masalah kosmetik, vitiligo iku kondisi normal lan ora nular. Ing dermatologi, perawatan sing paling efektif yaiku fototerapi utawa laser (excimer) 2–3 kali seminggu, paling sethithik 1 taun. Yen sampeyan ora bisa asring menyang rumah sakit amarga alesan finansial utawa kesibukan, sampeyan bisa nyoba mesin fototerapi sing disetujoni kanggo panggunaan ing omah.
Vitiligo ing kelopak mata
Vitiligo ing tangan.
relevance score : -100.0%
ReferencesVitiligo minangka kelainan kulit umum sing nyebabake bintik-bintik kulit putih amarga ilang melanosit. Riset anyar nuduhake manawa iku penyakit autoimun. Sanajan asring katon minangka masalah kosmetik, bisa uga mengaruhi kesejahteraan mental lan urip saben dina. Ing taun 2011, para ahli nggolongake jinis sing diarani segmental vitiligo kanthi kapisah saka jinis liyane.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Pasien vitiligo aktif duwe sawetara pilihan terapi, kayata glukokortikoid sistemik, fototerapi, lan imunosupresan sistemik. Pasien vitiligo sing stabil bisa memperoleh relief saka kortikosteroid topikal, inhibitor calcineurin topikal, fototerapi, lan prosedur transplantasi. Kemajuan anyar kanggo ngerteni proses dhasar vitiligo wis nyebabake pangembangan terapi sing ditargetake. Saiki, inhibitor JAK dadi sing paling menjanjikan, menehi toleransi sing apik lan asil fungsional, sanajan ana risiko ngaktifake infeksi laten lan efek samping sistemik sing umum karo agen imunosupresif liyane. Panaliten sing terus ditindakake kanggo ngenali sitokin utama sing melu pangembangan vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Pamblokiran sitokin kasebut wis nuduhake janji ing model kewan lan sawetara pasien. Kajaba iku, investigasi babagan miRNA-based therapeutics lan adoptive Treg cell therapy lagi ditindakake.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ora ana obat sing bisa nyembuhkan vitiligo. Kanggo wong kanthi kulit terang, panggunaan tabir surya lan perawatan kulit sing tepat iku rekomendasi utama. Pilihan perawatan liya bisa kalebu krim steroid utawa fototerapi.
○ Pengobatan
#Phototherapy
#Excimer laser
#Tacrolimus ointment